Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Biogen and UCB stay the course for phase III lupus success
Biogen and UCB's anti-CD40L candidate, dapirolizumab pegol, met primary endpoint in phase III lupus trial, showing improvement over placebo and standard of care at 48 weeks.
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly's Alzheimer's drug, donanemab, approved by Japan's health ministry, offering another treatment option after Eisai and Biogen's Leqembi. Kisunla, sold in the U.S., slows memory and thinking problems by 29% but has risks of brain swelling and bleeding. Unlike Leqembi, Kisunla has finite dosing, allowing patients to stop treatment when amyloid plaques are no longer visible.
UCB, Biogen lupus drug scores in phase 3 trial
UCB and Biogen's phase 3 trial of dapirolizumab pegol for systemic lupus erythematosus (SLE) was successful, with clinical improvement in primary and secondary endpoints. A second trial, PHOENICS FLY, is expected to start before year-end. If approved, dapirolizumab pegol could offer a new treatment for SLE, a chronic autoimmune disease affecting multiple organ systems.
Biotechnology Market Outlook: Growth, Share, Value, Size, and Insights
The biotechnology market, valued at USD 1023.92 Million in 2022, is projected to reach USD 10129.16 Billion by 2030 with a CAGR of 29.00%. Driven by personalized medicine, R&D advancements, and investments, key players like Roche and Thermo Fisher Scientific Inc. are leading innovation. Segmented by technology, application, and end-user, the market spans healthcare, agriculture, and industrial biotechnology, among others.
UCB And Biogen Lifted By Promising Late-Stage Lupus Data
Article sent to my@email.address. All fields required; separate multiple recipients with a semicolon. Active subscribers access full article; others directed to abstract.
Phase 3 results for Dapirolizumab Pegol in Systemic Lupus Erythematosus
UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus (SLE), with plans to advance to a second Phase 3 study in 2024. Dapirolizumab pegol, a humanized, Fc-free polyethylene glycol-conjugated antigen-binding fragment, targets the CD40L pathway to reduce B cell activation and autoantibody production, offering a potential new treatment option for SLE.
Biogen, UCB Score Phase III Lupus Victory After Mid-Stage Stumble
Biogen and UCB's drug candidate dapirolizumab pegol met primary efficacy endpoint in Phase III PHOENYCS GO study for systemic lupus erythematosus, showing greater improvement of moderate-to-severe disease activity at 48 weeks versus placebo. The treatment also demonstrated clinical improvements in key secondary endpoints. Safety profile was consistent with previous studies. Biogen and UCB plan to initiate another Phase III study, PHOENYCS FLY, this year. Full results to be presented at a medical congress.
Biogen: positive phase III data in lupus
UCB and Biogen announce positive Phase 3 PHOENYCS GO study results for dapirolizumab pegol in moderate-to-severe systemic lupus erythematosus (SLE), meeting primary endpoint with greater improvement in disease activity after 48 weeks compared to placebo.
UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released
UCB and Biogen's lupus drug met primary endpoint in Phase III PHOENYCS GO trial, showing greater improvement in moderate-to-severe SLE activity. The drug also improved secondary endpoints and maintained a consistent safety profile. UCB's stock rose 2.57% post-announcement. A new Phase III trial, PHOENYCS FLY, will start before year-end.
© Copyright 2025. All Rights Reserved by MedPath